Physician profile
Brad Colvin
NPI 1710956255
$4,612.76
in general payments reported to CMS, 2019-2025
26 companies · $726 in 2025
The $726 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.25 · 2020: $17.79 · 2021: $11.98 · 2023: $3,409 · 2024: $430 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $1,500 · Travel and Lodging: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.31 |
| Education | $1,500.00 |
| Travel and Lodging | $1,125.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,649.18 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Astellas Pharma US INC | $286.19 | 2023-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $209.01 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $163.55 | 2023-2025 | Myfembree |
| Organon LLC | $135.82 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $129.80 | 2023-2025 | |
| Abbvie INC. | $117.31 | 2023-2025 | Liletta, Orilissa |
| Sage Therapeutics, LLC | $99.18 | 2023-2025 | Zurzuvae |
| Myriad Women'S Health, INC. | $96.57 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $91.97 | 2023-2024 | |
| Hologic Sales and Service, LLC | $91.35 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Exeltis, USA INC. | $86.91 | 2023-2024 | Slynd |
| Evofem Biosciences, INC. | $66.91 | 2023-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $55.64 | 2023-2025 | |
| Millicent US INC | $49.01 | 2025 | Femlyv |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $45.32 | 2023-2024 | Contrave |
| Supernus Pharmaceuticals, INC. | $43.88 | 2025 | Qelbree |
| Novo Nordisk INC | $36.85 | 2025 | Wegovy |
| Avion Pharmaceuticals | $32.93 | 2023 | Balcoltra |
| Dexcom, INC. | $27.35 | 2025 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $18.78 | 2025 | Pico |
| Merck Sharp & Dohme LLC | $18.25 | 2019 | |
| Strongbridge US INC. | $17.79 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $16.15 | 2024 | |
| Becton, Dickinson and Company | $13.80 | 2023 | Bd Onclarity |
| Takeda Pharmaceuticals U.S.A., INC. | $13.26 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Colvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.